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Since the middle of the past century, identification of the causal gene for monogenic disorders has undoubtedly led to improvement in diagnostics and knowledge of the pathophysiological mechanisms underlying these disor-
ders. Yet an explanation for the often extensive variability in the clinical expression 
of diseases caused by variants in the same gene often remains elusive, and this is 
no less the case for Marfan syndrome (MFS). MFS is an autosomal dominant inher-
ited connective tissue disorder, caused by pathogenic variants in the fibrillin 1 gene 
(FBN1). This gene encodes the extracellular matrix protein, fibrillin1, which plays an 
essential structural role in the assembly of the microfibrils, as well as a functional 
role in the regulation of growth factors, such as transforming growth factor β and 
bone morphogenetic protein.1
MFS is a pleiotropic disease affecting predominantly the ocular, skeletal, and 
cardiovascular systems. Survival of patients with MFS is mainly determined by the 
degree of cardiovascular involvement. Progressive enlargement of the aortic root 
at the level of the sinuses of Valsalva in particular accounts for excess mortality 
because it may lead to life-threatening aortic dissection or rupture. Whereas the 
prognosis for people with MFS was initially bleak, mainly because of aortic compli-
cations, this has improved significantly for the past decades.2 This positive trend is 
not only because of optimization of medical and surgical treatment but also related 
to increased awareness and better diagnostics. Other cardiovascular features, pres-
ent in a variable amount of patients, include mitral valve prolapse and myocardial 
dysfunction.3,4
To date, treatment of cardiovascular manifestations in patients with MFS is fairly 
uniform, with guidelines for medical treatment and (prophylactic) surgery based 
on simple parameters, such as age, body surface, and aortic diameters. Neverthe-
less, we know that not everyone benefits from the same (standard) treatment 
and therefore the search for better methods for risk stratification and more per-
sonalized treatment strategies has been underway for a long time and embraces 
not only clinical parameters but also genetic and biological markers. Also, several 
recent studies have clearly established a sex difference, with men usually present-
ing a worse outcome compared with women.2,5–7
In addition to the clinical diversity in MFS, there is also an important variation in 
the nature of the (likely) pathogenic variants. To date, >3000 different pathogenic 
variants have been found in all regions of the FBN1 gene, including the full spectrum 
of variant types: missense variations, stop codons, splice site variants, insertion/
deletion, as well multiexon and whole-gene deletions.8 This vast range of variants 
offers an attractive prospect to investigate any links with the clinical expression 
of the disease. One of the major obstacles in the search for distinct effects of the 
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different variants, however, is that the precise mecha-
nism of organ damage in MFS is still elusive. Concep-
tually, it could be assumed that variants resulting in a 
truncated protein leading to nonsense-mediated mRNA 
decay (haploinsufficient-type effect, usually comprising 
nonsense and splice site variants, or small duplications/
deletions leading to out-of-frame effects) would result 
in a different clinical expression than variants leading to 
a stable but mutant fibrillin protein (dominant negative 
[DN]-type effect, usually comprising missense variants). 
Experimental research, however, demonstrated that a 
reliable prediction of the ultimate effect of a FBN1 vari-
ant on the protein is not straightforward.
Indeed, it has been shown that premature truncat-
ing codon variants can also have a DN effect and like-
wise that missense variants, usually leading to a stable 
mutant protein, can cause degradation of the protein 
leading to a haploinsufficient effect.9–11 These experi-
ments indicate that a simple classification of variants in 
haploinsufficient and DN groups may not be complete-
ly reliable. Indeed targeted functional studies for each 
variant would be required for correct categorization.
Despite this complexity in appropriately classifying 
FBN1 variants, some fairly consistent results through-
out the literature have been found: (1) The clustering of 
pathogenic variants in the neonatal region (exons 25–
33) in the extremely rare and severe form of neonatal 
MFS,8 (2) The association of missense variants affecting 
a cysteine residue with the presence of ectopia len-
tis, and 8,10,12 (3) Higher rate of aortic events in those 
patients carrying a truncating variant or a variant with a 
haploinsufficient effect.12–16
A summarized overview of published genotype-
cardiovascular phenotype studies in MFS is provided 
in the Table—more extended information is provided 
in the Table in the Data Supplement. In addition to 
some differences in categorizing the FBN1 variants, 
classification of cardiovascular manifestations also 
lacks consistency, further hampering comparison of 
these results.
In the study by Takeda et al,20 published in this issue, 
a cohort of 248 Japanese patients were included. A vast 
majority (225; 90.7%) fulfilled the diagnostic criteria for 
MFS—the remaining 23 being children in whom the 
diagnosis is more challenging. Only those FBN1 variants 
fulfilling the American College of Medical Genetics and 
Genomics-Association for Molecular Pathology criteria 
for pathogenicity (≥class 4) were considered. Nonsense, 
frameshift, out-of-frame exon skipping, and initiation 
codon variants were (theoretically) considered as having 
a haploinsufficient effect, and missense, in-frame inser-
tion/deletion, or exon skipping variants were considered 
to have a DN effect. The later ones were further divided 
in 2 categories: (1) missense affecting a cysteine residue 
or in-frame insertion/deletion, and (2) other missense 
or in-frame exon skipping. Severe aortic events were 
defined as occurrence of aortic root replacement, type A 
dissection, and related death. Remarkably, type B dissec-
tions were not considered in this category. Also of note 
Table. Summary of the Main Results of the Genotype–Phenotype 
Studies
No. of 
Subjects
Cardiovascular Genotype–Phenotype 
Correlations References
104 Higher prevalence of AoRD and MR in 
the PTC group in comparison to the 
missense affecting Cys (NS)
Schrijver et al10
76 Similar prevalence of AoRA and AoRD in 
patients with PTC, missense and splicing 
variants
Rommel et al12
1013 Similar cumulative prevalence of AoRA in 
patients with PTC and inframe variants
Higher probability of AoRA and MVP 
in patients with missense variants 
eliminating a Cys vs creating a Cys
Higher probability of AoRA, AoRR, and 
MV disease if in exon 24–32 (neonatal 
cases excluded)
Faivre et al8
965 Higher probability of AoRA, aortic event, 
and MVP patients with missense variants 
altering a Cys
Détaint et al2
149 Higher frequency of LV dilation 
in nonmissense variant carriers in 
comparison with missense
Aalberts et al17
179 Higher percentage of AoRR and AoRD 
occurring at younger ages in carriers 
of truncating and splice site variants in 
comparison to missense variants
Baudhuin et al14
117 Reduction of AoR growth rate by 
Losartan only in the haploinsufficient 
group, not in the DN group
Franken et al18
2223 PTC/frameshift/splice site: more frequent 
AoRD
Missense affecting Cys: not associated 
with increased risk of dissection
Bakkers19
357 Higher rate of AoRD and AoRR but not 
of death in the haploinsufficient group in 
comparison to DN group
Age at event did not differ between 
groups
Franken et al15
290 Larger AoR at baseline, higher AoR, 
and ascending aortic growth rate and 
increased risk of combined AoRD and 
death in the haploinsufficient group in 
comparison to the DN
Franken et al16
90 Higher prevalence of AoRR (either 
because of AoRA or AoRD) in carriers 
of truncating variants in comparison to 
missense variants
Becerra-Muñoz 
et al13
248 Higher rate of AoRD, AoRR or aortic-
related death occurring at younger 
ages in the haploinsufficient group in 
comparison to the DN group
Risk of aortic events was comparable 
between the DN-CD group and 
haploinsufficient group
Takeda et al20
AoR indicates aortic root; AoRA, aortic root aneurysm; AoRD, aortic root 
dissection; AoRR, aortic root replacement; Cys, cysteine; DN, dominant 
negative; DN-CD, missense affecting a cys residue; LV, left ventricle; MR, 
mitral regurgitation; MVP, mitral valve prolapse; NS, not significant; and PTC, 
premature terminating codon.
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is that the threshold for surgery in the Japanese study 
seems to be lower than the conventional threshold of 50 
mm, which may also be influencing the results. Consis-
tent with the findings in the literature, patients with vari-
ants predicted to have a haploinsufficient effect (n=93) 
were found to have more aortic events when compared 
with patients with DN effect variants (n=155) variants.
Although these findings are hopeful and may guide 
risk prediction to some extent, the well-known exten-
sive clinical inter- and interfamilial heterogeneity in MFS 
patients harboring the same variant cannot solely be 
explained by the type and location of the variant. Obvi-
ously, other factors must play a role in the expression of 
the disease, such as genetic modifiers or epigenetic and 
environmental factors.
One such factor also reported in this study by Takeda 
et al20 is the observation of differences in aortic pheno-
type between men and women. In a period of at least 
3 years, aortic growth rate was higher in men than in 
women aged <20 years (1.35 mm/y interquartile range, 
0.79–1.66 versus 0.71 mm/y interquartile range, 0.37–
1.08). Not only increased aortic growth rate but also 
higher occurrence rates for aortic surgery and dissec-
tion in men have been reported in several studies and 
definitely requires further attention.2,5 Recent research 
in mouse models for MFS also pointed to clear differ-
ences in aortic damage and possibly opens up further 
perspectives for treatment.7
Genotype–phenotype correlation studies in MFS 
such as this study by Takeda et al20 certainly help iden-
tifying paths toward a more personalized and precise 
medicine for patients with this condition. These data 
confirm previous findings that variants that are predict-
ed to result in an haploinsufficient effect on the protein 
are associated with a more severe aortic manifestations 
than variants leading to DN effects and that men pres-
ent more rapid aortic growth than women.
Options to move forward from here and find ways of 
translating these data into clinical practice include
1. A robust meta-analysis of the published results. 
An attempt has already been presented in 2016 
by Bakkers,19 analyzing 2223 published FBN1 vari-
ants for which data on aortic features were avail-
able. The risk for aortic dissection was increased 
in patients harboring nonsense, frameshift, and 
splicing variants when compared with missense 
variants affecting a cysteine residue, consistent 
with this study. In contrast to what is suggested 
in this study, missense mutations affecting cys-
teine were not associated with increased risk of 
dissection. Since the meta-analysis presented 
by Bakkers19 in 2016, 4 additional studies, the 
1 published in this issue included, counting 985 
subjects, have been published, therefore a new 
meta-analysis taking not only the type of variant 
into consideration should be considered.
2. Confimation of the results in large prospective 
cohorts: to this end, large international collab-
orative efforts offered by the European Reference 
Networks or the Montalcino Aortic Consortium 
should be used. In these prospective studies, 
other manifestations including myocardial func-
tion, as well as potential differences in drug 
response, need consideration.
3. Functional studies to elucidate the pathomecha-
nistic mechanisms of the different (groups of) 
variants. Animal (including mouse and zebrafish) 
studies as well as cell culture studies seem par-
ticularly suited for this purpose.
In conclusion, genotype–phenotype correlation stud-
ies have proven to be a interesting direction of research 
to refine risk prediction in MFS. Thus far, based on pub-
lished data and re-enforced by this study, variants with 
a presumed haploinsufficient effect seem to associate 
with worse cardiovascular outcome. However, better 
efforts to precisely define both the phenotype and the 
genotype are necessary to be able to apply these find-
ing in clinical practice.
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SUPPLEMENTAL MATERIAL 
Supplemental Table: Extended summary of the methodology and main results of the genotype-phenotype studies. 
 
 
Subjects and variants 
 
Variant Categories Phenotypic outcome parameters Genotype-Phenotype correlations Reference 
N subjects: 104 
Age: 34.2 yr 
Truncating variants 60 
PTC: Nonsense, frameshift 
out-of-frame exon skipping 
Missense involving a cys 
residue 
Ocular and skeletal features. 
Cardiovascular: AoRA, AoRD, AoRR, 
MVP, MR – all analysed separately 
Missense involving cys: higher prevalence of 
EL and retinal detachment 
PTC: more striking skeletal features 
AoRD and MR more prevalent in the PTC 
group (NS) 
Schrijver I. et al 
20021 
N subjects: 76 
Truncating variants 25 
Missense variants 43 
PTC: nonsense, frameshift 
Missense 
 Involving a cys 
residue 
 Not involving a cys 
residue 
Splicing 
El 
AoRA and AoRD combined 
AoRD separately 
Missense involving cys and splicing: higher 
prevalence of EL 
Prevalence of AoRA and AoRD was similar in 
all groups 
Rommel K. et al 
20052 
N subjects: 1013 
Age: 29yr (range 15-40) 
Sex: 547 males 
Truncating variants 417 
Missense variants 573 
PTC 
Missense 
 Involving a cys 
residue 
 Not involving a cys 
residue 
In-frame 
AoRA, AoRD, Dilatation or dissection 
of the descending or abdominal aorta 
before age 50 years, MVP, MR, aortic 
insufficiency, isolated aortic valvular 
surgery 
“Major and Minor cardiac 
involvement” (not defined) – all 
analyzed separately 
Missense involving cys: higher prevalence of 
EL than other missense 
PTC in comparison in inframe: higher skeletal 
involvement 
Similar cumulative prevalence of AoRA 
between PTC and inframe variants 
Higher probability of AoRA and MVP in 
patients with missense eliminating a cys 
compared to creating a cys 
More severe and complete phenotype if exon 
24-32 were affected (neonatal cases excluded) 
Faivre L. et al 
20073 
N subjects: 965 
Age: 22yr (IQR: 11-34 yr) 
Sex: 511 males 
Missense 
 Involving a cys 
residue 
 Not involving a cys 
residue 
PTC: nonsense, frameshift 
In-frame 
AoRA 
Aortic event (AoRD or AoRR) 
Most of the CV features were not significantly 
different between patients with (i) PTC vs 
inframe; (ii) with missense vs. nonsense or 
frameshift. 
Higher probability of AoRA, aortic event and 
MVP patients with variants altering a cys (all 
P, 0.03)  
Detaint D. et al 
20104 
N subjects: 149 
Age: 33.5±11.8yr 
Sex: 68 males 
Non-missense variants 74 
Missense 
 Involving a cys 
residue 
 Not involving a cys 
residue 
Left Ventricular dilatation Non-missense: higher frequency of LV 
dilation 
Aalberts JJ. et al 
20145 
Non-missense 
 In-frame 
 Nonsense 
 Frameshift 
 Splicing 
N subjects: 179 
Sex: 84 males 
Truncating variants 59 
Missense variants 96 
Truncating: nonsense, 
frameshift 
Missense 
Splicing 
Aortic dissection (type A and B) with 
or without surgical repair or 
prophylactic aortic surgery 
Truncating or splicing: higher percentage of 
aortic events occurring at younger ages 
Baudhuin LM. et 
al. 20156 
N subjects: 117 
Age: 35.3yr (range 18-71) 
Sex: 55 males 
HI variants 38 
HI: deletion of whole gene, 
deletion of exon 1 or 65, 
translation of < first 10 exons, 
nonsense and frameshift 
leading to null-allele, 
missense leading to protein 
degradation  
DN: missense leading to a 
stable protein, in-frame ins/del 
or exom skipping, nonsense 
and frameshift not leading to 
null-allele 
AoR growth rate HI: higher presence of pectus carinatum, dural 
ectasia and skin striae 
Reduction of AoR growth rate by Losartan 
only in the HI group 
Franken R. et al 
20157 
N subjects: 357 
Age: 36.5±13.5yr 
Sex: 184 males 
HI variants 146 
As previously described Primary endpoints: death and aortic 
dissection (type A and type B) 
Secondary endpoint: aortic surgery 
HI: higher rate of aortic event but not of 
death. Age at event did not differ from the DN 
group. 
Males: higher rate of aortic surgery but not of 
aortic dissection 
Franken R. et al 
20168 
N mutations: 2223 
HI: 941 
Missense 
 Involving a cys 
residue 
 Not involving a cys 
residue 
Non-missense 
 PTC 
 Frameshift 
 Splice site 
Aortic dissection PTC/frameshift/splice site: more frequent 
aortic dissection 
Missense affecting cys: not associated with 
increased risk of dissection 
Bakkers & Jeremy 
20169 
N subjects: 290 
Age: 30.2±14.7yr 
Sex: 140 males 
HI variants 113 
As previously described Aortic diameters and the aortic dilation 
rate at the level of the AoR, ascending 
aorta, arch, descending thoracic aorta 
and abdominal aorta by 
echocardiography 
Clinical endpoints: dissection and 
death 
DN: higher prevalence of EL 
HI: larger AoR at baseline, higher AoR and 
ascending aortic growth rate, increased risk of 
combined aortic dissection and death 
Franken R. et al. 
201710 
N subjects: 90 
Age: 31.44േ16.92yr 
Truncating: Nonsense, 
frameshift 
AoRR or dissection Missense: higher prevalence of EL Becerra- Muñoz 
VM. et al 201811 
Sex: 50 males 
35 truncating variants 
Missense 
Splicing 
Truncating: higher prevalence of systemic 
score >7 
Truncating: higher prevalence of aortic 
events 
N subjects: 248 
Age: 31.3yr (range 2-80) 
Sex: 128 males 
HI variants 93 
HI: nonsense, frameshift, out-
of-frame exon skipping 
initiation condon. 
DN: missense, in-frame 
ins/del or exon skipping 
 DN-CD: missense 
affecting a cys 
residue, in-frame 
ins/del 
 DN-nonCD: other 
missense, in-frame 
exon skipping 
AoRR, AoRD and related death HI: higher rate of aortic events occurring at 
younger ages 
DN-CD: comparable risk of aortic events as 
HI 
Males: higher rate of aortic events 
Takeda N. et al 
201812 
 
AoR: Aortic Root; AoRA: aortic root aneurysm; AoRD: Aortic Root Dissection; AoRR: Aortic Root replacement; Cys: cysteine; EL: Ectopia Lentis; MVP: 
Mitral Valve Prolapse; MR: mitral regurgitation; PTC: Premature Terminating Codon 
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